摘要
目的：探讨孟鲁司特联合匹多奠德防治小儿哮喘反复发作的临床疗效。方法：将107例支气管哮喘患儿采用随机数字表分为两组，观察组55例在ICS的基础加用盂鲁司特口服12个月及匹多莫德口服2个月，对照组52例仅给予ICS吸入治疗。两组均随访12个月，记录两组患儿哮喘发作次数和临床症状及住院或门诊留观天数。结果：观察组与对照纽显效率分别为57．5％和42％，总有效率分别为94．2％和74％（χ2=7．89，P〈0．01）。结论：在常规吸入ICS治疗后支气管哮喘仍有反复发作，予孟鲁司特联合匹多莫德口服可显著减少哮喘反复发作次数及发作时症状，疗效优于单独使用ICS，且两药联用无明显不良反应。
Objective To discuss the clinical efficacy of consociation of oral Montelukast with oral Pidotmod on preventing and treating the repeated attacks of asthma in children. Methods the 107cases of bronchial asthma were divided into two groups using a random number table. On the basis of ICS, the observation group of 55 eases was given oral Montelukast for 12 months and oral Pidotmod for 2 months. The contrast group of 52 cases was given the ICS inhalation alone. Both groups were followed up for 12 months, recording the frequency and clinical symptoms of asthma attacks, and the number of hospitalized days or days under observation. Results The marked effective rates of the observer Group and the contrast group were 57.5% and 42% respectively, and the total effective rates of the two groups were 94.2% and 74% respectively（x2=7.89,P〈0.01）. Conclusion Repeated attacks of asthma were found after the conventional treatment of ICS inhalation. With the remarked reduction of the frequeney and the symptom severity of asthma attacks, the efficacy of eonsociation of oral Montelukast with oral Pidotmod is better than ICS alone, with no obvious adverse reactions found.
